Product

Benefits of PseudoSense

  • Receive an answer within 60 seconds
  • On-the-spot analysis
  • Accurate results
  • Frequent monitoring
  • Immediate treatment upon positive answer

Our concept

At PreDiagnose we develop sensors capable of identifying a variety of microorganisms and health markers. All the sensors are compatible with the measuring device that wirelessly is controlled by your smartphone or tablet.

Following fluid collection, the user can put a drop of the sample on top of the sensor, which can then be plugged into the hardware. Data is acquired and sent via Bluetooth to the user’s smartphone, which will use a hidden algorithm (software) to analyse the collected data and provide an easy-to-read result    

PseudoSense

Pseudomonas aeruginosa (PA) infections are a major risk to patients with a compromised host defense mechanism such as those suffering from cystic fibrosis, primary ciliary disease, nosocomial pneumonia or urinary tract infections. Patients infected with PA are limited to late and poor diagnosis techniques. Consequently, they are left to deal with a difficult treatment, poorer life quality and shorter life expectancy. PseudoSense (Pseudomonas aeruginosa sensor) is a time- and cost-effective fast point-of-care device able to detect early and intermittent PA infections in a non-invasive manner.

Pseudomonas aeruginosa is the 2nd priority pathogen for which new antibiotics are urgently needed according to World Health Organisation.

Validation of PseudoSense

The proof of concept of PseudoSense has been tested on 62 cystic fibrosis patients for 9 months at the University Hospital of Copenhagen. The results showed 100 % accuracy and a detection time of 30 sec when compared to the traditional in vitro diagnostic test (58.8 % and 2-5 days, respectively).

Problem with current diagnostic tools

The treatment of PA infections is currently troublesome due to: a) the lack of early detection tools, allowing the bacteria to adapt by the diagnosis is established (up to 3.5 years after inception); b) patients are forced to go to the hospital frequently, where there is a higher risk of cross contamination; and d) high diagnostic costs associated with laboratory-assessment which take 2-5 days, thus limiting more frequent monitoring.

Our patentable method is capable of detecting bacteria before the conventional culturing. The early diagnosis of bacteria can be up to 3.5 years earlier than today.